Contributions
Abstract: P1892
Type: Poster
Abstract Category: Late breaking news
Background: The recently described association between repeated administration of gadolinium based contrast agents (GBCAs) and increased signal intensity (SI) in the dentate nucleus and globus pallidus on T1-weighted unenhanced magnetic resonance images is subject of debate. In a previous analysis, we found no effect of macrocyclic chelate type GBCAs in a small group of multiple sclerosis (MS) patients.
Objective: The aim of the study was to evaluate the changes in terms of signal intensity (SI) of dentate nucleus and globus pallidus on T1-weighted unenhanced magnetic resonance images after repeated administrations of GBCAs in a cohort of MS patients.
Methods and patients: Considering consecutive MS patients with normal baseline renal and liver functions we compared SI ratio changes on T1-weighted images (dentate nucleus-to-pons and globus pallidus-to-thalamus) after at least 3 administrations of macrocyclic chelate type GBCAs (gadobutrol, gadoteridol, and/or gadoterate meglumine). Each T1-weighted image series obtained on the same 1.5 T scanner has been randomly analysed by two readers, in consensus, with respectively 4 and 5 years of expertise. Readers were free to use processing tools such as windowing, gradation adjustment, and magnification. Renal and liver function parameters have also been considered.
Results: We enrolled 52 MS patients (38 females, 14 males; age 46,1±10,8 years), who underwent repeated.
GBCA administrations (median 5, range 3-8). The average total doses of gadobutrol, gadoteridol, and gadoterate meglumine were 32,6±14,5 ml, 14,0±2,9 ml, and 23,7±13,7 ml, respectively. After repeated administrations of GBCAs, no changes in dentate nucleus-to-pons and globus pallidus-to-thalamus SI ratios were observed (p=0,41 and p=0,89, respectively). Moreover, renal and liver functions remained within normal range and stable throughout the study, despite a slight but statistically significant increase of AST, ALT, and GGT levels and reduction of creatinine levels.
Discussion and conclusion: Our single-centre study showed the safety of repeated administration of macrocyclic chelate type GBCAs, with no effect on SI of the dentate nucleus and globus pallidus; our previous results have been confirmed in a larger cohort of MS patients.
Disclosure:
Arianna Sartori: nothing to disclose
Antonio Giulio Gennari: nothing to disclose
Irene Zorzenon: nothing to disclose
Alessandro Dinoto: nothing to disclose
Alessio Bratina: nothing to disclose
Maja Ukmar: nothing to disclose
Antonio Bosco: nothing to disclose
Maria Assunta Cova: nothing to disclose
Paolo Manganotti: nothing to disclose
Abstract: P1892
Type: Poster
Abstract Category: Late breaking news
Background: The recently described association between repeated administration of gadolinium based contrast agents (GBCAs) and increased signal intensity (SI) in the dentate nucleus and globus pallidus on T1-weighted unenhanced magnetic resonance images is subject of debate. In a previous analysis, we found no effect of macrocyclic chelate type GBCAs in a small group of multiple sclerosis (MS) patients.
Objective: The aim of the study was to evaluate the changes in terms of signal intensity (SI) of dentate nucleus and globus pallidus on T1-weighted unenhanced magnetic resonance images after repeated administrations of GBCAs in a cohort of MS patients.
Methods and patients: Considering consecutive MS patients with normal baseline renal and liver functions we compared SI ratio changes on T1-weighted images (dentate nucleus-to-pons and globus pallidus-to-thalamus) after at least 3 administrations of macrocyclic chelate type GBCAs (gadobutrol, gadoteridol, and/or gadoterate meglumine). Each T1-weighted image series obtained on the same 1.5 T scanner has been randomly analysed by two readers, in consensus, with respectively 4 and 5 years of expertise. Readers were free to use processing tools such as windowing, gradation adjustment, and magnification. Renal and liver function parameters have also been considered.
Results: We enrolled 52 MS patients (38 females, 14 males; age 46,1±10,8 years), who underwent repeated.
GBCA administrations (median 5, range 3-8). The average total doses of gadobutrol, gadoteridol, and gadoterate meglumine were 32,6±14,5 ml, 14,0±2,9 ml, and 23,7±13,7 ml, respectively. After repeated administrations of GBCAs, no changes in dentate nucleus-to-pons and globus pallidus-to-thalamus SI ratios were observed (p=0,41 and p=0,89, respectively). Moreover, renal and liver functions remained within normal range and stable throughout the study, despite a slight but statistically significant increase of AST, ALT, and GGT levels and reduction of creatinine levels.
Discussion and conclusion: Our single-centre study showed the safety of repeated administration of macrocyclic chelate type GBCAs, with no effect on SI of the dentate nucleus and globus pallidus; our previous results have been confirmed in a larger cohort of MS patients.
Disclosure:
Arianna Sartori: nothing to disclose
Antonio Giulio Gennari: nothing to disclose
Irene Zorzenon: nothing to disclose
Alessandro Dinoto: nothing to disclose
Alessio Bratina: nothing to disclose
Maja Ukmar: nothing to disclose
Antonio Bosco: nothing to disclose
Maria Assunta Cova: nothing to disclose
Paolo Manganotti: nothing to disclose